# PATENT COOPERATION TREATY

# PCT

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference P729PC00	FOR FURTHER ACTION as we	see Form PCT/ISA/220 'see Form PCT/ISA/220 '
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/DK2004/000205	25/03/2004	26/03/2003
Applicant Ostjysk innovation A/S		
according to Article 18. A copy is being tran	•	norlty and is transmitted to the applicant
This International Search Report consists o	if a total of <u>11</u> sheets. It copy of each prior art document cited in this	report.
Basis of the report     With regard to the language, the in language in which it was filed, unless	ternational search was carried out on the bas ss otherwise indicated under this item.	is of the international application in the
this Authority (Rule	23.1(b)).	ation of the international application furnished to
	d unsearchable (See Box II).	in the international application, see Box No. I.
3. X Unity of invention is lack!	,	
4. With regard to the title,  X the text is approved as substitute text has been established.	mitted by the applicant. ed by this Authority to read as follows:	
:		
5. With regard to the abstract, the text is approved as subn the text has been establishe may, within one month from	nitted by the applicant. d, according to Rule 38.2(b), by this Authority the date of mailing of this international search	v as it appears in Box No. IV. The applicant n report, submit comments to this Authority.
	applicant. Authority, because the applicant failed to sugg Authority, because this figure better characteri	

International application No.

PCT/DK2004/000205

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity, such as nephrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of blocking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds, more particularly gentamicin.

Box II C	Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)
This intern	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1 C	Claims Nos.: ecause they relate to subject matter not required to be searched by this Authority, namely:
bi ai	claims Nos.: ecause they relate to parts of the International Application that do not comply with the prescribed requirements to such a nextent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
3. C	laims Nos.: ecause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III O	bservations where unity of invention is lacking (Continuation of Item 3 of first sheet)
This Interna	ational Searching Authority found multiple inventions in this international application, as follows:
s	ee additional sheet
1. As	s all required additional search fees were timely paid by the applicant, this International Search Report covers all earchable claims.
2. As	s all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment any additional fee.
3. As	s only some of the required additional search fees were timely paid by the applicant, this International Search Report vers only those claims for which fees were paid, specifically claims Nos.:
	o required additional search fees were timely paid by the applicant. Consequently, this International Search Report is stricted to the invention first mentioned in the claims; it is covered by claims Nos.:  -37, 47-49 (all partially)
Řетаrk on	Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.:

remark: diaminomethane and piperidine are not compounds according to the structural definition of formula  ${\bf 1}$ 

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-37,47-49 (partially)

Use of a compound of formulae I-VI for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity.

2. claims: 1-37,47-49 (partially) 38-41

Use of a moiety of gentamicin for the manufacture of a medicament for the prophylaxis and/or treatment of induced cell toxicity.

3. claims: 47-49 (partially) 42-46

A compound of formula VII and uses thereof.

4. claims: 50-61

Method of reducing cell toxicity of a therapeutic agent comprising at least one cell toxic compound, said method comprising reducing the number of cationic groups from said at least one cell toxic compound.

International Application No

PCT/DK2004/000205 A. CLASSIFICATION OF SUBJECT MATTER
1PC 7 A61K31/132 A61K31/16 A61K31/198 A61K31/4196 A61K31/445 A61K31/495 A61K31/53 A61K31/7008 A61P39/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, CHEM ABS Data, WPI Data, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category 9 Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Х GB 1 364 521 A (MERCK & CO INC) 21 August 1974 (1974-08-21) the whole document WO 03/080103 A (MAX DELBRUECK CENTRUM; WILLNOW THOMAS (DE)) 2 October 2003 (2003-10-02) P,X 1,3,19, abstract; claims 1,18,30,31 page 9, line 15 - page 10, line 5 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 18. 11. 2004 24 August 2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

3

A. Jakobs

C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PC1/DR2004/000205
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	WO 02/053519 A (BURNS MARK ROBERT; BANDUIR NAND (US); ORIDIGM CORP (US); GRAMINSKI GE) 11 July 2002 (2002-07-11)	1,2,4-6, 19-21, 28, 35-37,
	abstract page 11, line 30 - page 21, line 5 page 36, lines 11-20 page 9, line 21 - page 10, line 6	47-49
x	WO 99/02145 A (DURANT GRAHAM J ; GWYNNE DAVID I (US); CAMBRIDGE NEUROSCIENCE INC (US)) 21 January 1999 (1999-01-21)	1-21,24, 28, 35-37, 47-49
	the whole document	47-49
<b>(</b>	EP 0 483 634 A (HOECHST ROUSSEL PHARMA) 6 May 1992 (1992-05-06)	1-5, 7-13, 15-21, 24,28, 35,47-49
	abstract page 3, line 12 - page 7, line 50; claims 1-14	
	DE 100 53 506 A (MAX DELBRUECK CENTRUM) 2 May 2002 (2002-05-02)	1,2, 4-11, 18-21, 28, 35-37,
	the whole document	47-49
	WO 89/05637 A (US BIOSCIENCE) 29 June 1989 (1989-06-29)	1,4-6, 19,36,
	abstract; examples 1-4 page 2, paragraphs 1,3	37,47-49
	US 6 177 434 B1 (KOPKE RICHARD D ET AL) 23 January 2001 (2001-01-23)	1-5, 7-13, 15-21, 24,28, 35,47-49
	abstract column 2, line 47	
	US 6 130 217 A (ARNOLD LEE DANIEL ET AL) 10 October 2000 (2000-10-10)	1,2,4, 7-13, 15-21, 28,35-37
	column 1, line 50 - column 21, line 20 abstract	20,35-3/
	-/	

	,	PCT/DK2004/000205
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MILAM K M ET AL: "REDUCTION IN CIS DIAMMINEDICHLOROPLATINUM-II-INDUCED CYTOTOXICITY SISTER CHROMATID EXCHANGE AND DNA INTERSTRAND CROSS-LINKS IN 9L CELLS TREATED WITH THE POLYAMINE BIOSYNTHESIS INHIBITOR 2R 5R-6 HEPTYNE-2 5-DIAMINE" CANCER RESEARCH, vol. 49, no. 24 PART 1, 1989, pages 6945-6948, XP008033957 ISSN: 0008-5472 abstract page 6946, column 2 - page 6947, column 2, paragraph 3; figure 1; tables 1,2	1,4-6, 19-21, 28,29, 32,33, 35-37, 47-49
Κ	HEYS, STEVEN D. ET AL: "Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomized controlled trial" INTERNATIONAL JOURNAL OF ONCOLOGY, 12(1), 221-225 CODEN: IJONES; ISSN: 1019-6439, 1998, XP008033963 abstract	1,4-6, 17, 19-21, 28,35, 36,47-49
	TOMIDA A ET AL: "NOVEL MECHANISM OF N SOLANESYL-N N'-BIS-3 4-DIMETHOXYBENZYLETHYLENEDI AMINE IN POTENTIATION OF ANTITUMOR DRUG ACTION ON MULTIDRUG-RESISTANCE AND SENSITIVE CHINESE HAMSTER CELLS" JAPANESE JOURNAL OF CANCER RESEARCH, vol. 82, no. 1, 1991, pages 127-133, XP008033945 ISSN: 0910-5050 abstract	1,2,4,5, 15-17, 19-21, 28, 35-37, 47-49
	WO 01/12607 A (DARRO FRANCIS; KISS ROBERT (BE); GUILLAUMET GERALD (FR); JOSEPH BENOI) 22 February 2001 (2001-02-22)  abstract page 2, line 27 - page 4, line 28 page 10, line 12 - page 12, line 4;	1,2,4, 7-13,15, 17-21, 28, 35-37, 47-49
	examples 32,33,35,37,38,58,59,61-66,73 page 112, line 4 - page 178, line 20	
	FAN DOMINIC ET AL: "Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol" INVESTIGATIONAL NEW DRUGS, vol. 12, no. 3, 1994, pages 185-195, XP008033946 abstract	1,2,4,5, 15-17, 19-21, 28, 35-37, 47-49

		PC1/DR2004/000205
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	. Relevant to claim No.
Catedota	oncline of coomitors, with moleculor, whose appropriate, or the relevant passages	. Field valit to Claims 140.
	LIN P K T ET AL: "The synthesis and in vitro cytotoxic studies of novel bis-naphthalimidopropyl polyamine derivatives" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 14, 17 July 2000 (2000-07-17), pages 1609-1612, XP004209715 ISSN: 0960-894X the whole document	1-37
A	EDWARDS M L ET AL: "POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY. POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, no. 5, 1 May 1990 (1990-05-01), pages 1369-1375, XP000604648 ISSN: 0022-2623 the whole document	1-37
X	WIEBKIN P ET AL: "INHIBITION OF METABOLISM MEDIATED CYTO TOXICITY BY 1 1 DI SUBSTITUTED HYDRAZINES IN MOUSE MASTO CYTOMA LINE P-815 CELLS" BIOCHEMICAL PHARMACOLOGY, vol. 31, no. 18, 1982, pages 2921-2928, XP001199476 ISSN: 0006-2952 the whole document	1
x .	KONDRATOV R V ET AL: "Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 24, 20 November 2001 (2001-11-20), pages 14078-14083, XP002259950 ISSN: 0027-8424 the whole document	1-5, 7-13, 15-22, 28, 35-37, 47-49
(,P	WO 03/066572 A (OCHSNER CYNTHIA E; COPP RICHARD R (US); FAHL KATHLEEN L (US); FAHL WI) 14 August 2003 (2003-08-14) the whole document	1,2,4-6, 19-21, 35-37, 47-49

Information on patent family members

							2004/000203
Patent do cited in sea			Publication . date .		Patent family member(s)		Publication date
GB 1364	1521	Α	21-08-1974	DE FR NL	2234804 2146295 7209320	A1	25-01-1973 02-03-1973
WO 0308	 80103	Α	 02-10-2003	WO	7209320  03080103		18-01-1973 
							02-10-2003
WO 0205	3519	Α	11-07-2002	CA EP JP WO US	2433807 1373185 2004529082 02053519 2003187276	A2 T A2	11-07-2002 02-01-2004 24-09-2004 11-07-2002 02-10-2003
WO 9902	145	Α	21-01-1999	AU WO	8278498 9902145	<del></del> -	08-02-1999 21-01-1999
EP 0483	634	A	06-05-1992	US AT AU CA DE DE DE GR HIE JP KR PT ZA	5039666 133072 640056 8680291 2054471 69116503 483634 0483634 2083500 3018824 60136 913775 99874 3003333 4282315 139199 99358 9108592	T B2 A A1 D1 T2 T3 A2 T3 A2 A1 A B2 A B1 A B	13-08-1991 15-02-1996 12-08-1993 07-05-1992 01-05-1992 29-02-1996 20-06-1996 20-05-1996 06-05-1992 16-04-1996 30-04-1996 28-08-1992 22-05-1992 31-08-1995 24-01-2000 07-10-1992 15-05-1998 30-09-1992 29-07-1992
DE 10053	3506	Α	02-05-2002	DE	10053506	A1	02-05-2002
WO 89056		A	29-06-1989	AT AU AU CA DE DE EP JP US WO	102826 629533 2922389 1328619 3888541 3885541 0391971 2951344 3503162 5292497 8905637	B2 A C D1 T2 A1 B2 T A	15-04-1994 08-10-1992 19-07-1989 19-04-1994 21-04-1994 23-06-1994 17-10-1990 20-09-1999 18-07-1991 08-03-1994 29-06-1989
US 61774	34	B1	23-01-2001	US	2001007871	A1	12-07-2001
US 61302	17	Α	10-10-2000	NONE			
WO 01126	07	A	22-02-2001	FR AU CA EP WO	2797444 7012200 2381968 1202971 0112607	A A1 A2	16-02-2001 13-03-2001 22-02-2001 08-05-2002 22-02-2001

Information on patent family members

Patent document cited in search report	1	Publication date		Patent family member(s)	Publication date
WO 0112607	Α		US	6645983 B1	11-11-2003
WO 03066572	Α	14-08-2003	CA WO US	2475349 A1 03066572 A1 2003185778 A1	14-08-2003 14-08-2003 02-10-2003